NCT06308575 2025-01-10
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
M.D. Anderson Cancer Center
Ohio State University
Alliance for Clinical Trials in Oncology
Vanderbilt University